Clinical and Commercialization Developments
Advancements in Clinical Manufacturing for Cancer Vaccines & Anti-Aging Skin Care
AIVITA Biomedical has developed proprietary methods for the scalable production of differentiated human cells in high-purity from human stem cells. The Company’s lead therapeutic candidate, an autologous dendritic-cell/tumor-cell cancer immunotherapy with platform applicability, is the result of more than two decades of cancer research combined with successive advancements of AIVITA’s proprietary manufacturing expertise. The Company has also leveraged and adapted its proprietary cell culture techniques to explore new areas of commercial opportunity, including a novel skin care technology launched in February 2017.